COSMO Pharmaceuticals N.V. header image

COSMO Pharmaceuticals N.V.

COPN

Equity

ISIN NL0011832936 / Valor 32590356

SIX Swiss Exchange (2026-05-07)
CHF 75.90+0.39%

COSMO Pharmaceuticals N.V.
UMushroom community rating:

star star star star star
4.00 2 votes No rating yet
NegativeNeutralPositive

About company

COSMO Pharmaceuticals N.V. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of gastrointestinal diseases. The company has successfully brought to market six approved drugs and two medical devices, addressing unmet medical needs in this therapeutic area. COSMO Pharmaceuticals is involved in the entire product lifecycle, from identifying medical needs and managing product development to obtaining regulatory approvals. The company licenses its approved products to partners with strong marketing and sales capabilities, ensuring effective market penetration. Additionally, COSMO offers a range of services related to pharmaceutical production, including the assessment of manufacturing processes, technology transfer, evaluation of product stability, market testing and release, and the preparation of necessary documentation for product registration.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results ():

Summarized from source with an LLMView Source

Key figures

58.6%1Y
39.5%3Y
-13.3%5Y

Performance

47.3%1Y
36.5%3Y
35.0%5Y

Volatility

Market cap

1596 M

Market cap (USD)

Daily traded volume (Shares)

105,520

Daily traded volume (Shares)

1 day high/low

63.8 / 61.5

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

4.00

2 votes
Performance:
starstarstarstarstar
3.50
Innovation:
starstarstarstarstar
4.50
Society:
starstarstarstarstar
4.00
Nature:
starstarstarstarstar
4.00
Andrei Khristoliubov
United Kingdom, 21 Feb 2026
star star star star star
.
Matthew Waterhouse
United Kingdom, 19 Feb 2026
star star star star star
.

EQUITIES OF THE SAME SECTOR

Omnicell Inc
Omnicell Inc Omnicell Inc Valor: 1275961
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.46%USD 43.76
Revolution Medicines Inc
Revolution Medicines Inc Revolution Medicines Inc Valor: 52143299
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
2.62%USD 151.07
Trupanion Inc
Trupanion Inc Trupanion Inc Valor: 24738737
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-3.82%USD 24.92
Alignment Healthcare Inc
Alignment Healthcare Inc Alignment Healthcare Inc Valor: 110387702
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.87%USD 18.14
TransMedics Group Inc
TransMedics Group Inc TransMedics Group Inc Valor: 47361695
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-23.19%USD 72.92
Neumora Therapeutics Inc
Neumora Therapeutics Inc Neumora Therapeutics Inc Valor: 129329732
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.30%USD 2.33
Gyre Therapeutics Inc
Gyre Therapeutics Inc Gyre Therapeutics Inc Valor: 130270397
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
3.34%USD 8.04
Evolent Health Inc
Evolent Health Inc Evolent Health Inc Valor: 28153126
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-2.05%USD 3.83
Udemy Inc
Udemy Inc Udemy Inc Valor: 114176816
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.27%USD 4.80
L'Oreal S.A.
L'Oreal S.A. L'Oreal S.A. Valor: 502805
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
3.33%EUR 367.00